Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment.

ABSTRACT:

Introduction

Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment (creatinine clearance ≤50 mL/min). In this post hoc analysis, we assessed the effect of saxagliptin 2.5 and 5 mg/day versus placebo on glycemic measures in patients with T2D and estimated glomerular filtration rate 45-60 mL/min/1.73 m(2).

Methods

Efficacy and safety data were pooled from nine 24-week, randomized, placebo-controlled clinical trials.

Results

The majority (56-61%) of patients were women aged <65 years with glycated hemoglobin (A1C) 8.1-8.2%; half of the patients had a T2D duration ≥5 years. Mean change from baseline in A1C was signif

SUBMITTER: Perl S 

PROVIDER: S-EPMC5014790 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature